Close Menu

NEW YORK – Abbott said after the close of the market on Friday that the US Food and Drug Administration issued Emergency Use Authorization for the company's point-of-care test for detection of SARS-CoV-2.

According to the Abbott Park, Illinois-based firm, the test, which will run on its ID Now platform, can provide positive results in as little as five minutes and negative results in 13 minutes, and it can be used in a variety of healthcare settings, including doctors' offices, urgent care clinics, and hospital emergency departments.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.